Cipla shares gained over 2 percent on December 17 after Kotak Institutional Equities upgraded the stock to a 'buy' from its previous 'add' rating. The upgrade was driven by factors such as reasonable valuations, a series of upcoming US launches, expectations of domestic recovery, and healthy growth in South Korea.Along with the rating upgrade, Kotak assigned a price target of Rs 1,725 for the stoc...

Stocks in NewsLet's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, and fund-raising, here’s a quick look at which stocks will be in focus in today's trade:Results TodayHero MotoCorp, Grasim Industries, Brainbees Solutions Firstcry, Honasa Consumer Mamaearth, Glenmark Pharmaceuticals, Ipca Laboratories, Bajaj Healthcare, Bharat ...

The market attempted to extend the previous day's rally but selling pressure in late trade pulled it down to close marginally lower on October 9. However, the market breadth remained positive due to buying in the broader space, with about 1,708 shares advancing against 802 declining shares on the NSE. Volatility is expected to continue in the market, with support at the current week's low. Below a...

Brokerage firm Investec has kept a bullish stance on drugmaker Cipla, banked on expectations of mid-teens growth in the India pharma market, and easing regulatory challenges at its Goa plant.The brokerage remains optimistic of Cipla achieving 12-13 percent on-year growth in sales within the Indian pharma market. Alongside that, Investec also sees a classification from the US Food and Drug Administ...

Cipla Ltd shares have been making higher highs and higher lows, indicating bullish signals across all major time frames. The pharma sector has been in the limelight for the past few sessions, with Nifty Pharma reaching a 52-week high at 19,771.According to Arun Kumar Mantri, Founder of Mantri Finmart, "The stock-specific volumes have been encouraging in the latest bullish move, followed by good pr...